339 related articles for article (PubMed ID: 28531203)
21. Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma.
Hoyle M; Green C; Thompson-Coon J; Liu Z; Welch K; Moxham T; Stein K
Value Health; 2010; 13(1):55-60. PubMed ID: 19804431
[TBL] [Abstract][Full Text] [Related]
22. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China.
Shi G; Park SH; Ren H; Xue M; Lu X; Dong P; Gao X
J Med Econ; 2018 Dec; 21(12):1150-1158. PubMed ID: 30134758
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective.
Capri S; Porta C; Delea TE
Clin Ther; 2017 Mar; 39(3):567-580.e2. PubMed ID: 28189363
[TBL] [Abstract][Full Text] [Related]
24. First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis.
Wan X; Zhang Y; Tan C; Zeng X; Peng L
JAMA Oncol; 2019 Apr; 5(4):491-496. PubMed ID: 30789633
[TBL] [Abstract][Full Text] [Related]
25. Economic burden of adverse events in patients with metastatic renal cell carcinoma.
Hagiwara M; Borker R; Oster G
Clin Ther; 2013 Dec; 35(12):1955-1963.e2. PubMed ID: 24290735
[TBL] [Abstract][Full Text] [Related]
26. The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic renal cancer.
Collinson FJ; Gregory WM; McCabe C; Howard H; Lowe C; Potrata D; Tubeuf S; Hanlon P; McParland L; Wah T; Selby PJ; Hewison J; Brown J; Brown J
BMC Cancer; 2012 Dec; 12():598. PubMed ID: 23241439
[TBL] [Abstract][Full Text] [Related]
27. Outcomes and Drug Costs of Sunitinib Regimens for Metastatic Renal Cell Carcinoma: A Provincial Population-Based Study.
Suo A; Iqbal U; Lim J; Lee C; Gesy K; Iqbal N; Abbas T
Clin Genitourin Cancer; 2017 Jun; 15(3):e397-e404. PubMed ID: 28216279
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.
Ravasio R; Ortega C; Sabbatini R; Porta C
Clin Drug Investig; 2011; 31(7):507-17. PubMed ID: 21627339
[TBL] [Abstract][Full Text] [Related]
29. Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.
Pal SK; Signorovitch JE; Reichmann WM; Li N; Koo V; Liu Z; Perez JR; Vogelzang NJ
Clin Genitourin Cancer; 2016 Apr; 14(2):160-7.e3. PubMed ID: 26707954
[TBL] [Abstract][Full Text] [Related]
30. Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma.
Chen CC; Hess GP; Liu Z; Gesme DH; Agarwala SS; Garay CC; Hill JW; Guo A
Clin Genitourin Cancer; 2012 Dec; 10(4):256-61. PubMed ID: 22682982
[TBL] [Abstract][Full Text] [Related]
31. Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study.
Choueiri TK; McDermott D; Sheng Duh M; Sarda SP; Neary MP; Oh WK
Urol Oncol; 2012; 30(6):848-55. PubMed ID: 20926319
[TBL] [Abstract][Full Text] [Related]
32. Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison.
Vargas C; Balmaceda C; Rodríguez F; Rojas R; Giglio A; Espinoza MA
Expert Rev Pharmacoecon Outcomes Res; 2019 Oct; 19(5):609-617. PubMed ID: 30758237
[No Abstract] [Full Text] [Related]
33. Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.
Maroun R; Fleury L; Nachbaur G; Maunoury F; Vanhille JL; Durand-Zaleski I
Curr Med Res Opin; 2017 Oct; 33(10):1755-1762. PubMed ID: 28748721
[TBL] [Abstract][Full Text] [Related]
34. Current and predicted cost of metastatic renal cell carcinoma in Finland.
Purmonen T; Nuttunen P; Vuorinen R; Pyrhönen S; Kataja V; Kellokumpu-Lehtinen P
Acta Oncol; 2010 Aug; 49(6):837-43. PubMed ID: 20331406
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma.
Hoyle M; Green C; Thompson-Coon J; Liu Z; Welch K; Moxham T; Stein K
Value Health; 2010; 13(1):61-8. PubMed ID: 19804430
[TBL] [Abstract][Full Text] [Related]
36. [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
Siebels M; Staehler M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H;
Aktuelle Urol; 2010 Mar; 41(2):122-30. PubMed ID: 19937556
[TBL] [Abstract][Full Text] [Related]
37. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ
J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893
[TBL] [Abstract][Full Text] [Related]
38. "Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy.
Harrison MR; George DJ; Walker MS; Chen C; Korytowsky B; Kirkendall DT; Stepanski EJ; Abernethy AP
Clin Genitourin Cancer; 2013 Dec; 11(4):441-50. PubMed ID: 23856102
[TBL] [Abstract][Full Text] [Related]
39. Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.
Hess G; Borker R; Fonseca E
Clin Genitourin Cancer; 2013 Jun; 11(2):161-7. PubMed ID: 23267717
[TBL] [Abstract][Full Text] [Related]
40. Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma-Results From a Tertiary Cancer Center in India.
Ramaswamy A; Joshi A; Noronha V; Patil VM; Kothari R; Sahu A; Kannan RA; Sable N; Popat P; Menon S; Prabhash K
Clin Genitourin Cancer; 2017 Jun; 15(3):e345-e355. PubMed ID: 28077238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]